Novo Nordisk foundation to place more grants outside Denmark
The foundation receives its funds from the wholly owned subsidiary Novo Holdings, through which it controls Wegovy maker Novo Nordisk as well as other companies.
This author has not written his bio yet.
But we are proud to say that Reuters Health contributed 4158 entries already.
The foundation receives its funds from the wholly owned subsidiary Novo Holdings, through which it controls Wegovy maker Novo Nordisk as well as other companies.
The company stated it would cap out-of-pocket costs for its inhaled respiratory products at $35 per month in the United States, following a similar move by rival Boehringer Ingelheim earlier in the month.
Biden is also ordering his administration to report on progress they are making to erase gender gaps in research and to study how to use artificial intelligence to improve women’s health research, according to an administration document summarizing the order.
U.S. Secretary of State Antony Blinken was speaking at an annual meeting of the U.N. Commission on Narcotic Drugs (CND), which reviews global drug regulation and each year adds new so-called precursor chemicals – ingredients used to make illicit drugs – to international lists known as schedules to place strict controls on their trade.
Merck said its blockbuster immunotherapy Keytruda, in combination with chemoradiotherapy, met the main goal of improving overall survival for newly diagnosed patients with a form of cervical cancer in a late-stage study.
A company executive stated that Gilead will be able to quadruple production of its cell therapy cancer treatments by 2026 due to improvements in the U.S. biotech’s manufacturing processes.
Revenue from AstraZeneca’s rare diseases portfolio, boosted by the $39 billion acquisition of Alexion in 2021, has swelled in recent years, to nearly $7.8 billion in 2023.
The deal, which is expected to close by April 15, 2024, includes the acquisition of insulin brands Basalog and Insugen which Eris said will help its diabetes treatment franchise reach 10 billion rupees in revenue, without specifying a timeline.
Staff reviewers said that the pattern of early deaths observed in patients treated with both the therapies in their respective trials raised uncertainty about the treatments’ overall survival benefit in patients.
Ionis Pharmaceuticals said on Wednesday its experimental drug to treat a type of fatty liver disease met the main goal of reducing inflammation of the critical organ in a mid-stage trial.